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Key messages
The 2018 WHO draft guidelines on dietary saturated fatty acids and trans
fatty acids recommend reducing total intake of saturated fat and replacing
it with polyunsaturated and monounsaturated fatty acids
The recommendations fail to take into account considerable evidence
that the health effects of saturated fat varies depending on the specific
fatty acid and on the specific food source
Maintaining general advice to reduce total saturated fatty acids will work
against the intentions of the guidelines and weaken their effect on chronic
disease incidence and mortality
A food based translation of the recommendations for saturated fat intake
would avoid unnecessary reduction or exclusion of foods that are key
sources of important nutrients
Non-communicable diseases are the world’s leading cause of
death, responsible for 72% of the 54.7 million deaths in 2016.1
Cardiovascular diseases are responsible for approximately 45%
of all deaths from non-communicable diseases, with modifiable
risk factors such as diet, physical activity, smoking, and alcohol
intake being major causes of disease.
Among dietary factors, the World Health Organization considers
saturated fatty acids and trans fatty acids to be important.
Consensus exists on the health benefits of eliminating
industrially produced trans fatty acids—that it will reduce
incidence of cardiovascular disease and mortality.2 Foods
containing more than 2% total fat as trans fat were banned in
Denmark in 2004, and similar legislation is soon to be
implemented throughout the European Union. In the United
States the Food and Drug Administration no longer considers
industrial trans fats to be “generally regarded as safe.”
Many governments consider WHO dietary guidelines to be state
of the art scientific evidence, translating them into regional and
national dietary recommendations. These guidelines have
potential health implications for billions of people, so the
consistency of the science behind such recommendations and
the validity of the conclusions are crucial. Here, we look at the
evidence linking saturated fat intake and cardiovascular risk
and find that the WHO draft guidelines have excluded some
important aspects and studies.
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WHO draft guidelines
WHO draft guidelines on dietary saturated and trans fatty acids
for adults and children were published for consultation in May
2018. They recommend reducing intake of total saturated fatty
acids to less than 10% of total energy consumption and replacing
with polyunsaturated fat and monounsaturated fat to reduce
incidence of cardiovascular disease and related mortality.2 But
this fails to take into account considerable evidence that the
health effects vary for different saturated fatty acids and that
the composition of the food in which they are found is crucially
important (box 1).4-6 Food composition has a substantial effect
on lipid digestion, absorption kinetics, and postprandial
lipaemia,3 which is an independent risk factor for cardiovascular
disease.7
Box 1: Saturated fat in food products3
Saturated fatty acids are found in a wide diversity of foods that vary in
composition and structure, resulting in different physiological effects. Stearic
acid in dark chocolate, palmitic acid in meat, and heptadecanoic acid in dairy
products have completely different physiological effects. Moreover, the food
matrix in which the fatty acids exist has major importance for these effects.
Dairy products, for example, have very different compositions and milk fat
structures. Full fat milk is a natural emulsion of fat globules enclosed in milk
fat globule membrane, but when homogenised the fat droplets become much
smaller and covered with proteins. Butter is a water in oil emulsion. Yoghurt
is a fermented food containing live cultures, in which milk fat globules are
dispersed in a gelled milk protein matrix. Cheese is one of the most complex
dairy matrices. It is a fermented food containing live cultures, where fat is
present in milk fat globules and sometimes as “free fat inclusions,” in a solid
matrix rich in milk proteins, calcium, and milk fat globule membrane. Ice cream
contains a combination of crystallised fat globules around air bubbles and ice
crystals in a liquid syrup phase.
Foods from other animal sources that contain saturated fatty acids also have
a wide range of compositions and structures. Animal fats, such as lard and
tallow, are 100% lipids. In unprocessed meat, lipids are mostly in adipocytes
and intracellular lipid droplets of muscle. Processed meats can contain fat
inclusions in a gelled protein matrix, free fat domains, and remnant adipocytes,
depending on the type of processing. Egg yolk contains lipids structured as
lipoproteins of both low and high density.
In processed foods such as pastries and biscuits (cookies) the fat inclusions
(composed of palm oil, butter, or other fats) are embedded in a solid,
carbohydrate matrix, often rich in sugar. Chocolate is composed of particles
(sugar) and fermentation products from cocoa beans embedded in solid fat.
Vegetable oils that are rich in saturated fatty acids, such as palm oil and
coconut oil, are 100% lipids.
The saturated fatty acids in these different foods are also present as different
types of lipid molecules—notably triglycerides and phospholipids. In these
molecules, saturated fatty acids can be esterified at different positions
depending on the source of fat.
How robust is the evidence linking
saturated fat to cardiovascular disease?
Evidence from randomised controlled trials
with clinical endpoints
Several recently published meta-analyses of observational
studies and randomised controlled trials (RCTs) have found that
total saturated fat is not associated with non-communicable
diseases including coronary heart disease, cardiovascular
disease, and all cause mortality.8-10 By contrast, a Cochrane
analysis that included data from only 15 RCTs found an
association between reduced intake of saturated fat and a
decrease in the composite endpoint of cardiovascular events
(relative risk 0.83, 95% confidence interval 0.72 to 0.96). But
it also found no significant association between reducing
saturated fatty acids and total mortality (0.97, 0.90 to 1.05),
cardiovascular disease mortality (0.95, 0.80 to 1.12), fatal and
non-fatal myocardial infarction (0.90, 0.80 to 1.01), non-fatal
myocardial infarction (0.95, 0.80 to 1.13), stroke (1.00, 0.89 to
1.12), coronary heart disease events (0.87, 0.74 to 1.03), and
coronary heart disease mortality (0.98, 0.84 to 1.15).11
Evidence from randomised controlled trials
with surrogate endpoints
The WHO draft guidance relies heavily on a meta-analysis of
84 RCTs that tested the effect of modifying saturated fat intake
on serum lipid and lipoprotein concentrations, including low
density lipoprotein (LDL) cholesterol, and the ratio of total
cholesterol to high density lipoprotein cholesterol.12 This
approach—which focuses on total saturated fatty acids, ignores
food sources, and uses surrogate endpoints—is problematic for
several reasons.
First, not all saturated fatty acids are equal; the magnitudes and
even directions of the effects on both surrogate and long term
endpoints vary depending on fatty acid. Using the ratio of total
cholesterol to high density lipoprotein cholesterol as a biomarker
of cardiovascular disease risk, for example, is a problem because
the ratios are different for lauric acid (12:0) myristic acid (14:0),
palmitic acid (16:0), and stearic acid (18:0).13 Moreover, high
plasma concentrations of the heptadecanoic acid (17:0) are
associated with a reduced risk of coronary heart disease.14 Thus,
saturated fatty acids cannot be viewed as one homogeneous
group with regard to effects of diet on disease risk.
Second, it is unclear whether the observed changes in serum
lipoproteins translate into a reduction in cardiovascular
endpoints and mortality regardless of food source.4 Most trials
included in the meta-analysis did not investigate whole food
sources of saturated fat. Instead, some studies compared the
effect of diets supplemented with fats rich in saturated fatty
acids, monounsaturated fat, or polyunsaturated fat (such as cocoa
butter, olive oil, soybean oil, and dairy butter) and others used
fats not commonly found in diets (such as synthetic fats high
in myristic acid).12 The food matrix in which the fatty acids exist
(box 1) might be more important for the effect on cardiovascular
disease risk than the saturated fat content (see supplementary
file online).
Third, the meta-analysis mainly used LDL cholesterol
concentration as a marker for cardiovascular disease risk, which
could lead to erroneous conclusions. The atherogenicity of LDL
particles is determined by, among other things, size. Small and
medium LDL particles show the strongest association with risk
of cardiovascular disease, whereas large particles show no
association.15 The rise in serum LDL cholesterol concentration
from total saturated fat consumption has been linked to a parallel
increase in particle size, so it might not translate into an
increased risk of cardiovascular disease.16
The PURE study, which included over 100 000 people, shows
why a broader view of biomarkers of cardiovascular disease is
needed to inform guidelines. It found that diets high in saturated
fatty acids were associated not only with higher serum
concentrations of LDL cholesterol, but also with higher
concentrations of HDL cholesterol, lower concentrations of
triglycerides, and a lower apolipoprotein B:apolipoprotein A
ratio.17 The study also found that diets high in saturated fat were
not associated with cardiovascular disease events, except for a
lower risk of stroke.18 The relevance of this observation is
confirmed by at least three randomised trials comparing diets
with different fats on clinical endpoints.10 19 20
Mediterranean-style diets were associated with a significant
reduction in major cardiovascular disease events without any
reduction in LDL cholesterol in the Lyon Diet Heart Study19
and in updated analyses of the PREDIMED trial,20 which both
showed that LDL cholesterol concentration is not a valid
biomarker for alterations in cardiovascular disease risk caused
by dietary changes.
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Reanalysis of the Minnesota Coronary Experiment (a double
blind randomised controlled trial that tested whether replacing
saturated fat with polyunsaturated fat reduced coronary heart
disease and death) also supports the claim that serum cholesterol
is not a valid surrogate biomarker for cardiovascular disease
risk when making dietary changes.10 Despite the finding that
the polyunsaturated fat diet produced a 13% greater reduction
in serum cholesterol than the saturated fat diet, there was no
reduction in cardiovascular disease endpoints.10
The reanalysis found a 22% higher mortality for each 0.78
mmol/L reduction in serum cholesterol caused by the
polyunsaturated diet.10 A meta-analysis found that cholesterol
lowering using polyunsaturated fat diets did not show any
evidence of benefit on mortality from coronary heart disease
(1.13, 0.83 to 1.54) or all cause mortality (1.07, 0.90 to 1.27).10
Evidence from observational studies and food
based analyses of cardiovascular disease
risks
The WHO draft guidelines exclude substantial evidence derived
from observational studies and meta-analyses of prospective
cohort studies. The guideline argues that the quality of evidence
for relevant outcomes from such studies is lower than from
analyses of RCTs and that it was not possible to assess the
potential differential effects of replacing saturated fatty acids
with different nutrients. But observational studies are valuable
for assessing the association between saturated fat and long term
endpoints, such as cardiovascular disease.8 9 21
Observational studies are also useful for examining the foods
consumed in people’s diets rather than examining individual
nutrients. Longstanding evidence indicates that the food matrix
is more important than its fatty acid content for predicting the
effect of a food on risk of coronary heart disease. This was the
conclusion of an expert consensus panel, that some of us took
part in, nearly 10 years ago.21 Ample food based studies have
examined whether foods with high saturated fat content, which
are likely to be consumer targets for the WHO recommendation,
contribute to cardiovascular disease events and mortality (table
1). A recommendation to reduce intake of total saturated fat
without considering specific fatty acids and food sources is not
evidence based; will distract from other more effective food
based recommendations; and might cause a reduction in the
intake of nutrient dense foods that decrease the risk of
cardiovascular disease, type 2 diabetes, other serious
non-communicable diseases, malnutrition, and deficiency
diseases and could further increase vulnerability to nutrient
deficiencies in groups already at risk.
Discussion
To understand why the current misconceptions about saturated
fat are so solidly anchored in major public health bodies,
including WHO, we must consider the historical evolution of
guidelines.
Up until the 1950s nutrition science focused on single nutrients,
and major public health policies focused on deficiencies in
micronutrients, leading to fortification of selected staple foods;
for example, iodine in salt and vitamin B3 and iron in wheat
flour and bread.4 Nutrition science then changed focus to policies
for preventing chronic diseases such as cardiovascular disease
in affluent countries, and the single nutrient approach was
maintained. This was based mainly on cross country
comparisons between saturated fat intake and cardiovascular
disease mortality. The simple two step deductive reasoning that
“dietary fat, and saturated fat in particular, increases serum
cholesterol” and “serum cholesterol is a risk factor for coronary
heart disease” led to the conclusion that all dietary fat, and
saturated fat in particular, should be reduced to prevent
cardiovascular disease.4 The US dietary guidelines published
in 1980, and international guidelines ever since, have focused
on reducing intake of saturated fat.
Guidelines have an immense effect on dietary advice for
individuals and the production of ready to eat meals and meals
served in restaurants. Historically, the focus on reducing
saturated fat led to the proliferation of industrially produced
food products low in fat, saturated fat, and cholesterol and to
the dissemination of products based on technologies to replace
saturated fat. One example is the production of margarine and
spreads based on partial hydrogenation of vegetable oils, which
increased the content of trans fatty acids from zero to up to 40%
of total fat.34
The widespread consumption of trans fat is considered to have
been responsible for 6% to 19% of all coronary heart disease
events in the US in 200635 and to have caused about 2700 deaths
annually and loss of 570 000 life years in the UK every year.36
Denmark banned trans fats in 2004, and analyses have attributed
the subsequent larger decline in coronary heart disease mortality
in Denmark than in other EU countries to the elimination of
trans fat from foods.37
Scientific and policy missteps may have led to many
unnecessary deaths globally, and lessons should be learned. We
think that recommendations to reduce intake of total saturated
fat without considering specific fatty acids and food sources are
not based on evidence and will distract from other, more
effective, food based recommendations. Recommendations to
reduce saturated fat might cause a reduction in the intake of
nutrient dense foods that are important for preventing disease
and improving health. We’re concerned that, based on several
decades of experience, a focus on total saturated fat might have
the unintended consequence of misleading governments,
consumers, and industry towards promoting foods low in
saturated fat but rich in refined starch and sugar.
The WHO guidelines on saturated fat should consider different
types of fatty acids and, more importantly, the diversity of foods
containing saturated fatty acids that might be harmful, neutral,
or even beneficial in relation to major health outcomes. We
strongly recommend a more food based translation of how to
achieve a healthy diet and reconsideration of the draft guidelines
on reduction in total saturated fatty acids.
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Table
Table 1| Nutrient dense foods that also contain substantial amounts of saturated fat
Evidence linking food to cardiovascular disease and diabetesNutrientsFood
No association with coronary heart disease, reduced risk of stroke. RCT data show
that two eggs a day has beneficial effects on cardiovascular disease biomarkers,22 23
and improved glycaemic control in type 2 diabetes24
13 essential vitamins and minerals (eg, vitamin D, riboflavin,
iodine), high quality protein, α-linolenic acid (n-3), lutein,
zeaxanthin, and choline
Eggs
The WHO draft guidelines state that stearic acid has no harmful effect on “any
outcome assessed.” Meta-analyses of observational evidence find dark chocolate
consumption to be associated with a substantial reduction in risk of cardiovascular
disease.25 26 RCTs find beneficial effects on cardiovascular disease biomarkers (HDL
and LDL cholesterol, blood pressure, etc)27
Stearic acid is the major saturated fat. Also rich in fibre, iron,
magnesium, potassium, phosphorus, zinc, and selenium.
Contains polyphenols, flavanols, and catechins. Contains
added sugar
Dark
chocolate
Meta-analyses of food based observational studies find that cheese intake is
associated with slightly reduced risk of cardiovascular disease.28 29 Mechanistic studies
and RCTs show that cheese intake has favourable effects on biomarkers of
cardiovascular disease (blood lipids and blood pressure) and that these effects cannot
be predicted based on content of total saturated fat and sodium30 31
Full fat cheese is high in medium and long chain saturated
fatty acids (C13:0, C20:0, C18:2t10c12, and C20:2n-6), a wide
diversity of typical bioactive fatty acids (conjugated linoleic
acid, phytanic acid, trans palmitoleic acid), protein, calcium,
magnesium, and lactic acid bacteria (that produce short chain
fatty acids), and has a complex matrix structure
Cheese
Meta-analyses of observational studies find that intake of processed meat, but not
red meat, is associated with a higher risk of coronary heart disease, which indicates
that processing or factors other than the saturated fat content are responsible for
any link to cardiovascular disease.32 A meta-analysis found no difference in
cardiovascular disease risk factors between groups with more and less than 0.5 daily
servings of meat33
Meat is a major source of high quality protein, bioavailable
iron, minerals, and vitamins, but is also a source of saturated
fat
Meat
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